1319 related articles for article (PubMed ID: 6451045)
1. Genetically appropriate expression of HLA and DR (IA) alloantigens on human melanoma cell lines.
Pollack MS; Livingston PO; Fogh J; Carey TE; Oettgen HF; Dupont B
Tissue Antigens; 1980 Mar; 15(3):249-56. PubMed ID: 6451045
[TBL] [Abstract][Full Text] [Related]
2. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
Pollack MS; Heagney SD; Livingston PO; Fogh J
J Natl Cancer Inst; 1981 Jun; 66(6):1003-12. PubMed ID: 7017212
[TBL] [Abstract][Full Text] [Related]
3. Loss of polymorphic restriction fragments of class I and class II MHC genes in a malignant melanoma.
Angelini G; Fossati G; Radice P; Longo A; Piccioli P; Pierotti MA; Ferrara GB; Parmiani G
J Immunogenet; 1986; 13(2-3):241-6. PubMed ID: 2880915
[TBL] [Abstract][Full Text] [Related]
4. Tissue Typing of cultured human tumor cell lines: the detection of genetically appropriate HLA-A, B, C, and DR alloantigens.
Pollack MS; Heagney S; Fogh J
Transplant Proc; 1980 Mar; 12(1):134-7. PubMed ID: 7368285
[No Abstract] [Full Text] [Related]
5. Functional characteristics and differential expression of class II DR, DS, and SB antigens on human melanoma cell lines.
Pollack MS; Chin-Louie J; Moshief RD
Hum Immunol; 1984 Feb; 9(2):75-87. PubMed ID: 6607912
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism of human B-cell alloantigens: evidence for three loci within the HLA system.
Markert ML; Cresswell P
Proc Natl Acad Sci U S A; 1980 Oct; 77(10):6101-4. PubMed ID: 6160591
[TBL] [Abstract][Full Text] [Related]
7. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
[TBL] [Abstract][Full Text] [Related]
8. Heated lymphocytes express HLA-DR antigens despite their inability to stimulate in MLC.
Brewer JA; Hank JA; Wendel T; Schmeling GJ; Blank JL; Morrissey LW; Robins HI; Sondel PM
Tissue Antigens; 1983 Oct; 22(4):246-56. PubMed ID: 6228035
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic heterogeneity of HLA products on human melanoma cells.
Parmiani G; Taramelli D; Anichini A; Andreola S; Cascinelli N; Fossati G
J Immunogenet; 1986; 13(2-3):235-40. PubMed ID: 3469277
[TBL] [Abstract][Full Text] [Related]
10. HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes.
Guerry D; Alexander MA; Herlyn MF; Zehngebot LM; Mitchell KF; Zmijewski CM; Lusk EJ
J Clin Invest; 1984 Jan; 73(1):267-71. PubMed ID: 6606651
[TBL] [Abstract][Full Text] [Related]
11. HLA-DR antigens of autologous melanoma and B lymphoblastoid cell lines: differences in glycosylation but not protein structure.
Alexander S; Hubbard SC; Strominger JL
J Immunol; 1984 Jul; 133(1):315-20. PubMed ID: 6609984
[TBL] [Abstract][Full Text] [Related]
12. Major histocompatibility restriction of antigen recognition by T cells in a recipient of haplotype mismatched human bone marrow transplantation.
Chu E; Umetsu D; Rosen F; Geha RS
J Clin Invest; 1983 Sep; 72(3):1124-9. PubMed ID: 6193142
[TBL] [Abstract][Full Text] [Related]
13. HLA and DR antigen frequencies in melanoma patients: possible relation to disease prognosis.
Pollack MS; Livingston PO
Tissue Antigens; 1985 Oct; 26(4):262-5. PubMed ID: 3878014
[TBL] [Abstract][Full Text] [Related]
14. The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells.
Taramelli D; Fossati G; Balsari A; Marolda R; Parmiani G
Int J Cancer; 1984 Dec; 34(6):797-806. PubMed ID: 6334655
[TBL] [Abstract][Full Text] [Related]
15. Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization.
Muczynski KA; Anderson SK; Pious D
J Immunol; 1998 Apr; 160(7):3207-16. PubMed ID: 9531276
[TBL] [Abstract][Full Text] [Related]
16. Recombinant interferon-gamma can induce the expression of HLA-DR and -DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens.
Carrel S; Schmidt-Kessen A; Giuffrè L
Eur J Immunol; 1985 Feb; 15(2):118-23. PubMed ID: 3918869
[TBL] [Abstract][Full Text] [Related]
17. Human B-cell alloantigens DC1, MT1, and LB12 are identical to each other but distinct from the HLA-DR antigen.
Shackelford DA; Mann DL; van Rood JJ; Ferrara GB; Strominger JL
Proc Natl Acad Sci U S A; 1981 Jul; 78(7):4566-70. PubMed ID: 6974868
[TBL] [Abstract][Full Text] [Related]
18. Primary but not metastatic human melanomas expressing DR antigens stimulate autologous lymphocytes.
Fossati G; Taramelli D; Balsari A; Bogdanovich G; Andreola S; Parmiani G
Int J Cancer; 1984 May; 33(5):591-7. PubMed ID: 6233227
[TBL] [Abstract][Full Text] [Related]
19. Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells.
Maio M; Gulwani B; Morgano A; Ferrone S
Int J Cancer; 1989 Sep; 44(3):554-9. PubMed ID: 2506138
[TBL] [Abstract][Full Text] [Related]
20. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition.
Pandolfi F; Boyle LA; Trentin L; Kurnick JT; Isselbacher KJ; Gattoni-Celli S
Cancer Res; 1991 Jun; 51(12):3164-70. PubMed ID: 1904004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
